Folic Acid–Conjugated PLGA Nanoparticles of Eugenol: Development, Characterization, and In Vitro Cytotoxicity Studies on Breast Cancer Cell Line.
Background: The primary goal of the study was to develop folic acid–conjugated eugenol‐loaded PLGA nanoparticles for the treatment of breast cancer. Eugenol is reported to have potent anticancer activity. Entrapment of eugenol in folic acid–conjugated polymeric nanoparticles is expected to enhance i...
| Publicado en: | BioMed Research International Vol. 2026; pp. 1 - 14 |
|---|---|
| Autores principales: | , , , , |
| Formato: | equations & formulas research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
4/27/2026
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=193280603&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 193280603 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 23146133 FT2T jtl: BioMed Research International issn: 23146133 maglogo: N pubinfo: dt: 4/27/2026 vid: 2026 pid: 480 pub: Wiley-Blackwell place: Malden, Massachusetts artinfo: ui: 193280603 193280603 193280603 10.1155/bmri/2898012 193280603 ppf: 1 ppct: 13 formats: fmt: – @attributes: type: T – @attributes: type: C – @attributes: type: P tig: atl: Folic Acid–Conjugated PLGA Nanoparticles of Eugenol: Development, Characterization, and In Vitro Cytotoxicity Studies on Breast Cancer Cell Line. aug: au: Kashyap, Bhawna Khan, Azhar Malik, Tabarak Kapoor, Deepak N. Banerjee, Baisakhi affil: Faculty of Applied Sciences and Biotechnology,, Shoolini University,, Solan, Himachal Pradesh,, India, shooliniuniversity.com sug: subj: Breast Neoplasms Drug Therapy Folic Acid Administration and Dosage Biocompatible Materials Essential Oils Nanoparticles Plant Extracts Drug Development Evaluation Drug Efficacy Evaluation Cell Line, Tumor Drug Effects Antineoplastic Agents Pharmacodynamics In Vitro Studies Chromatography, Liquid Magnetic Resonance Spectroscopy Antiinflammatory Agents Pharmacodynamics Antioxidants Pharmacodynamics Chromatography, High Pressure Liquid Descriptive Statistics Analysis of Variance Post Hoc Analysis Data Analysis Software Cell Viability Drug Effects Dose-Response Relationship, Drug ab: Background: The primary goal of the study was to develop folic acid–conjugated eugenol‐loaded PLGA nanoparticles for the treatment of breast cancer. Eugenol is reported to have potent anticancer activity. Entrapment of eugenol in folic acid–conjugated polymeric nanoparticles is expected to enhance its availability at the cancer site and improve overall efficacy in breast cancer treatment. Method: Eugenol was isolated by the column chromatography technique. The isolated bioactive fraction was characterized by IR and NMR analyses. Polymeric NPs were prepared by the solvent emulsification–diffusion method and conjugated with FA by the EDC coupling method. The in vitro release profile for FA‐conjugated eugenol‐loaded PLGA NPs was evaluated by the dialysis membrane technique. Further in vitro anti‐inflammatory activity, in vitro antioxidant assays, and cytotoxicity studies were carried out. Results: NPs exhibiting particle size ranging from 444.2 to 928.3 nm, zeta potential ranging from −32.0 to −37.7 mV, entrapment efficiency ranging from 76.97% to 87.51%, and percent conjugation were found to be 72.59%–79.68%. The in vitro drug release profiles of the formulations were most effectively described by the Higuchi kinetic model, indicating that the mechanism governing drug release is primarily attributed to diffusion. The FTIR study indicated that there is no chemical modification of the drug, confirming its compatibility with other excipients. The morphology of the NPs was analyzed by FESEM analysis. The particulate nature of NPs showed homogenous, spherical shapes of NPs. The cell cytotoxicity studies on MDA‐MB‐231 cell lines exhibited enhanced cytotoxicity of the NPs. Conclusion: In conclusion, it was found that FA‐conjugated PLGA NPs can be a suitable platform for the targeted administration of eugenol for BC treatment. pubtype: Academic Journal doctype: equations & formulas research tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|